CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

3.68
-0.19  -5%
Previous Close 3.87
Open 3.84
Price To Book 2.08
Market Cap 14,677,801
Shares 3,988,533
Volume 217,858
Short Ratio 0.38
Av. Daily Volume 359,196
Stock charts supplied by TradingView

NewsSee all news

  1. Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

    Topline results from NASH Phase II study expected Q1 2020 Namodenoson has already been out-licensed for NASH in China and South Korea Namodenoson article on NASH recently published in International Journal of

  2. Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

    Reached agreement with U.S. FDA on Phase III liver cancer study design & initiated compassionate use program in Israel Signed new distribution deal for Piclidenoson in South Korea Entered into strategic

  3. Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will

  4. Can-Fite Granted Patents for its Sexual Dysfunction Drug

    The drug's unique mechanism of action will allow potential treatment in diabetic patients Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs

  5. Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

    Company currently evaluating potential partnerships with animal health pharmaceutical companies Treatment of arthritis in canines is an estimated $1.9 billion annual market with unmet need for safe and effective oral

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Glaucoma
Phase 2 data did not meet primary endpoint - March 27, 2019. Phase 3 trial to be initiated 2H 2020.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 continues to enrol as of August 29, 2019.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 2018 continues to enrol as of August 29, 2019.
Piclidenoson (CF101)
Psoriasis
Phase 2 data due 1Q 2020.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

    Topline results from NASH Phase II study expected Q1 2020 Namodenoson has already been out-licensed for NASH in China and South Korea Namodenoson article on NASH recently published in International Journal of

  2. Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

    Reached agreement with U.S. FDA on Phase III liver cancer study design & initiated compassionate use program in Israel Signed new distribution deal for Piclidenoson in South Korea Entered into strategic

  3. Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will

  4. Can-Fite Granted Patents for its Sexual Dysfunction Drug

    The drug's unique mechanism of action will allow potential treatment in diabetic patients Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs

  5. Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

    Company currently evaluating potential partnerships with animal health pharmaceutical companies Treatment of arthritis in canines is an estimated $1.9 billion annual market with unmet need for safe and effective oral

  6. Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

    Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson The Company recently completed a successful End-of-Phase II meeting with

  7. U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

    Successful conclusion of an End of Phase II meeting with the FDA Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver

  8. Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

    Topline results expected Q1 2020 Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases,

  9. Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine

    In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a

  10. Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference

     International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research A Phase III study protocol for Namodenoson in the treatment of advanced liver cancer CPB7 patients has been developed

  11. Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

    Cannabinoids bind to A3AR, the target of Can-Fite's drugs Can-Fite's unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology

  12. Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and

  13. Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

     Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II